Stella Diagnostics Inc.
SLDX · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.04 | 0.03 | -0.00 |
| FCF Yield | -0.33% | -16.78% | -2.03% | -0.92% |
| EV / EBITDA | -19.35 | -2.84 | -3.97 | -2.79 |
| Quality | ||||
| ROIC | 8.37% | 100.84% | 17.39% | 35.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.05 | 0.29 | 0.26 | 0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 96.56% | -524.54% | 24.33% | -118.31% |
| Safety | ||||
| Net Debt / EBITDA | -5.37 | -1.09 | -1.49 | -0.43 |
| Interest Coverage | 0.00 | 0.00 | -7.87 | -15.60 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |